BRAF and non-small cell lung carcinoma: Patients with NSCLC harboring BRAFnon-V600 alterations are a heterogeneous population in terms of clinicopathologic characteristics, genomic landscape, and BRAF kinase domain activity.18 These patients are currently orphans of targeted therapies and are treated as nononcogene-addicted, representing a relevant unmet clinical need.